New psoriasis drug tested in everyday clinics across china
NCT ID NCT06512337
First seen Feb 02, 2026 · Last updated May 14, 2026 · Updated 12 times
Summary
This study looks at how well deucravacitinib works for adults with moderate plaque psoriasis in everyday medical practice in China. Researchers will track 153 participants to see if their skin clears up and how much it improves. The goal is to understand the drug's real-world effectiveness beyond controlled trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 0001
Guangzhou, Guangdong, 510091, China
-
Local Institution - 0002
Handan, Hebei, 056029, China
-
Local Institution - 0003
Beijing, 102218, China
-
Local Institution - 0004
Shanghai, Shanghai Municipality, 200080, China
-
Local Institution - 0005
Dalian, Liaoning, 116021, China
Conditions
Explore the condition pages connected to this study.